ClinicalTrials.gg

Program

aumolertinib

Also written as “Almonertinib”, “Aumolertinib” and “HS-10296”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 4 companies.

Furthest: phase 3, since Nov 23, 201815 company-led studies, 8 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group85 open or runningphase 3since Nov 23, 2018Nov 28, 2016none ahead
Jiangsu HengRui Medicine43 open or runningphase 3since Sep 12, 2025Apr 2, 2019Jul 30, 2027phase 2 · NCT05503888
EQRx International20 open or runningphase 3since Jun 24, 2022Nov 5, 2021none ahead
Revolution Medicines10 open or runningphase 1since Jul 13, 2021Jul 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2016First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT02981108 · 364 enrolled · United States
  2. Nov 23, 2018Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT03849768 · 429 enrolled · China
  3. Apr 2, 2019Jiangsu HengRui Medicine's first study: phase 2 study in EGFR-mutant Non-Small Cell Lung CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT03904823 · 58 enrolled · China
  4. Dec 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT04687241 · 192 enrolled · China
  5. Jun 10, 20213 phase 3 studies in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT04923906, NCT04951648, NCT04951635
  6. Jul 13, 2021Revolution Medicines's first study: phase 1 study in NSCLCNew to Revolution MedicinesRevolution Medicines · NCT04969965 · 45 enrolled · United States, New Zealand
  7. Nov 5, 2021EQRx International's first study: phase 1 study in Severe Hepatic ImpairmentNew to EQRx InternationalEQRx International · NCT05199610 · 12 enrolled · United States
  8. Jun 24, 2022Phase 3 study in NSCLCEQRx International · NCT05493501 · 8 enrolled · United States
  9. Aug 8, 2022Phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT05503888 · 160 planned
  10. Oct 24, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT06110663 · 314 planned
  11. Jul 31, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT07130916 · 20 planned · Bosnia and Herzegovina, Bulgaria, Moldova
  12. Sep 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07183189 · 582 enrolled · China
  13. Sep 30, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07863167 · 660 planned · China

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in RecurrenceJiangsu HengRui Medicine · NCT05503888
  2. Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07863167
  3. Nov 2032Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungJiangsu HengRui Medicine · NCT07183189

TargetBeta

EGFR →read by rule
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07863167Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingJiangsu HengRui MedicineDec 30, 2028660
NCT07183189Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingJiangsu HengRui MedicineNov 2032582
NCT07130916Carcinoma, Non-Small-Cell Lung · Bosnia and Herzegovina, Bulgaria, Moldova1RecruitingHansoh Pharmaceutical GroupAug 9, 202520
NCT06110663Carcinoma, Non-Small-Cell Lung3Not yet recruitingHansoh Pharmaceutical GroupDec 30, 2024314
NCT05503888Recurrence2Not yet recruitingJiangsu HengRui MedicineJul 30, 2027160
NCT05493501NSCLC · United States3TerminatedEQRx InternationalAug 31, 20238
NCT05199610Severe Hepatic Impairment · United States1CompletedEQRx InternationalApr 1, 202312
NCT04969965NSCLC · United States, New Zealand1CompletedRevolution MedicinesOct 7, 202145
NCT04951648Carcinoma, Non-Small-Cell Lung · China3UNKNOWNHansoh Pharmaceutical GroupOct 4, 2023220
NCT04951635Carcinoma, Non-Small-Cell Lung · China3RecruitingHansoh Pharmaceutical GroupJul 15, 2024150
NCT04923906Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingHansoh Pharmaceutical GroupJun 18, 2024624
NCT04687241Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingHansoh Pharmaceutical GroupJul 8, 2024192
NCT03904823EGFR-mutant Non-Small Cell Lung Cancer · China2UNKNOWNJiangsu HengRui MedicineDec 202258
NCT03849768Carcinoma, Non-Small-Cell Lung · China3UNKNOWNHansoh Pharmaceutical GroupJan 15, 2021429
NCT02981108Carcinoma, Non-Small-Cell Lung · United States2UNKNOWNHansoh Pharmaceutical GroupJan 5, 2019364

How it is read

Names in the registry

  • “Almonertinib”, 3 entries
  • “Aumolertinib”, 2 entries
  • “aumolertinib”, 2 entries
  • “HS-10296”, 2 entries
  • “almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.